CD4 and mantle cell lymphoma: Consistently, the fraction of CD8+ T cells was significantly lower in samples of the ibrutinib nonresponders, with no significant changes observed in the fraction of total T cells or CD4 T cells between the responders and nonresponders (Fig. 6d), suggesting that CD8 T-cell depletion most likely contributed to therapeutic resistance in refractory MCL.